Brodalumab: A new way to inhibit IL-17 in psoriasis

被引：31

作者：

Facheris, Paola ^{[1
,2
]}

Valenti, Mario ^{[1
,2
]}

Pavia, Giulia ^{[1
,2
]}

Guanziroli, Elena ^{[1
]}

Narcisi, Alessandra ^{[1
]}

Borroni, Riccardo G. ^{[1
,2
]}

Costanzo, Antonio ^{[1
,2
]}

机构：

[1] Humanitas Clin & Res Ctr IRCCS, Dermatol, Milan, Italy

[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

DERMATOLOGIC THERAPY | 2020年 / 33卷 / 03期

关键词：

brodalumab; IL17-RA; psoriasis; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; ANTI-INTERLEUKIN-17-RECEPTOR ANTIBODY; SUSCEPTIBILITY LOCI; ATOPIC-DERMATITIS; INTERLEUKIN; 17A; CELLS; PHARMACOKINETICS; PATHOGENESIS; SECUKINUMAB;

D O I：

10.1111/dth.13403

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis is a chronic inflammatory disease that affects 2% to 4% of the population; about 20% of the patients present a moderate-to-severe form. The IL-23/Th17/IL-17 molecular axis is considered crucial in the pathogenesis of psoriasis and IL-17 is fundamental in the maintenance of the immune and inflammatory alterations causing psoriasis. Expression of IL-17A, IL-17F, and IL-17C is strongly increased in psoriatic plaques. Effective therapy leads to restoration of the expression of a wide range of genes (including effector cytokines and chemokines downstream of IL-17) to near normal levels. Brodalumab is the first biologic drug targeting specifically the subunit A of the IL-17 receptor (IL-17RA) and thus inhibiting not only IL-17A but also other members of the IL-17 family. Brodalumab is very effective and safe in treating moderate-to severe psoriasis.

引用

页数：9

共 44 条

[1] New insights of T cells in the pathogenesis of psoriasis [J].

Cai, Yihua ;

Fleming, Chris ;

Yan, Jun .

CELLULAR & MOLECULAR IMMUNOLOGY, 2012, 9 (04) :302-309

[2] Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis [J].

Chandran, Vinod ;

Raychaudhuri, Siba P. .

JOURNAL OF AUTOIMMUNITY, 2010, 34 (03) :J314-J321

[3] Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis [J].

Chiricozzi, Andrea ;

Guttman-Yassky, Emma ;

Suarez-Farinas, Mayte ;

Nograles, Kristine E. ;

Tian, Suyan ;

Cardinale, Irma ;

Chimenti, Sergio ;

Krueger, James G. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (03) :677-687

[4] Innate IL-17-producing cells: the sentinels of the immune system [J].

Cua, Daniel J. ;

Tato, Cristina M. .

NATURE REVIEWS IMMUNOLOGY, 2010, 10 (07) :479-489

[5] Population Pharmacokinetics of Brodalumab in Healthy Adults and Adults With Psoriasis From Single and Multiple Dose Studies [J].

Endres, Christopher J. ;

Salinger, David H. ;

Koeck, Kathleen ;

Gastonguay, Marc R. ;

Martin, David A. ;

Klekotka, Paul ;

Nirula, Ajay ;

Gibbs, Megan A. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11) :1230-1238

[6] Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin [J].

Esaki, Hitokazu ;

Brunner, Patrick M. ;

Renert-Yuval, Yael ;

Czarnowicki, Tali ;

Thy Huynh ;

Tran, Gary ;

Lyon, Sarah ;

Rodriguez, Giselle ;

Immaneni, Supriya ;

Johnson, Donald B. ;

Bauer, Bruce ;

Fuentes-Duculan, Judilyn ;

Zheng, Xiuzhong ;

Peng, Xiangyu ;

Estrada, Yeriel D. ;

Xu, Hui ;

Strong, Christina de Guzman ;

Suarez-Farinas, Mayte ;

Krueger, James G. ;

Paller, Amy S. ;

Guttman-Yassky, Emma .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (06) :1639-1651

[7]

European Medicines Agency, 2017, SUMM PROD CHAR KYNTH

[8] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis [J].

Gordon, K. B. ;

Blauvelt, A. ;

Papp, K. A. ;

Langley, R. G. ;

Luger, T. ;

Ohtsuki, M. ;

Reich, K. ;

Amato, D. ;

Ball, S. G. ;

Braun, D. K. ;

Cameron, G. S. ;

Erickson, J. ;

Konrad, R. J. ;

Muram, T. M. ;

Nickoloff, B. J. ;

Osuntokun, O. O. ;

Secrest, R. J. ;

Zhao, F. ;

Mallbris, L. ;

Leonardi, C. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :345-356

[9] Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory [J].

Gordon, K. B. ;

Kimball, A. B. ;

Chau, D. ;

Viswanathan, H. N. ;

Li, J. ;

Revicki, D. A. ;

Kricorian, G. ;

Ortmeier, B. G. .

BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) :705-715

[10] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials [J].

Griffiths, Christopher E. M. ;

Reich, Kristian ;

Lebwohl, Mark ;

van de Kerkhof, Peter ;

Paul, Carle ;

Menter, Alan ;

Cameron, Gregory S. ;

Erickson, Janelle ;

Zhang, Lu ;

Secrest, Roberta J. ;

Ball, Susan ;

Braun, Daniel K. ;

Osuntokun, Olawale O. ;

Heffernan, Michael P. ;

Nickoloff, Brian J. ;

Papp, Kim .

LANCET, 2015, 386 (9993) :541-551

← 1 2 3 4 5 →